MNG965
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.376
- BILE_ACID_METABOLISM+0.336
- COAGULATION+0.319
- PANCREAS_BETA_CELLS+0.260
- KRAS_SIGNALING_DN+0.251
- CHOLESTEROL_HOMEOSTASIS+0.250
- ESTROGEN_RESPONSE_LATE+0.250
- XENOBIOTIC_METABOLISM+0.247
- GLYCOLYSIS+0.227
- ESTROGEN_RESPONSE_EARLY+0.215
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.445
- IL6_JAK_STAT3_SIGNALING-0.346
- E2F_TARGETS-0.311
- INTERFERON_GAMMA_RESPONSE-0.306
- INFLAMMATORY_RESPONSE-0.300
- G2M_CHECKPOINT-0.285
- INTERFERON_ALPHA_RESPONSE-0.250
- MYC_TARGETS_V1-0.235
- TNFA_SIGNALING_VIA_NFKB-0.228
- PROTEIN_SECRETION-0.213
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613710 | — | F | 0.842 |
| 2 | SRR8613741 | — | F | 0.811 |
| 3 | SRR8518125 | — | F | 0.781 |
| 4 | MNG1264 | — | — | 0.768 |
| 5 | TCGA-OR-A5J3-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.764 |
| 6 | MNG290 | — | — | 0.764 |
| 7 | 59364db9-7bf7-4a15-9798-8e3886078012 | — | — | 0.763 |
| 8 | 290b89f5-2a44-424b-b77d-a190dcb93e07 | — | — | 0.760 |
| 9 | MNG247 | — | — | 0.758 |
| 10 | ae30907a-a08a-44f3-b656-b0ba9729c8e7 | — | — | 0.754 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.376 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.336 | Inavolisib | — uncovered |
| COAGULATION | 0.319 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.251 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.247 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.227 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.215 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.178 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.165 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.152 | Idelalisib | — uncovered |
| HYPOXIA | 0.151 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.132 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.106 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.105 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.095 | Inavolisib | — uncovered |
| MYOGENESIS | 0.089 | Inavolisib | — uncovered |